COVID-19 Impact and Recovery Analysis- Influenza Medication Market
The Influenza Medication Market – Global Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis.
Influenza also known as seasonal flue strongly prevails across major part of the world. The burden of influenza is increasing significantly around the worlds and depends on multiple parameters with time of the season, characteristics of the virus, and status of vaccination being the most influencing parameters. According to the World Health Organization, the burden of the seasonal flu or influenza is increasing annually around the globe. Influenza viruses are of four types, type A, B, C, and D. Among these, type A & B are responsible for the spread of pandemics. The type A influenza viruses are further classified into the hemagglutinin (HA) and the neuraminidase (NA) based on the type of the protein on the surface of the virus. The recent influenza pandemic was caused in 2009 due to type A (H1N1) also known as Swine Flu accounted for 12,469 deaths in the United States only. The healthcare authorities around the globe are continuously engaged in development of effective and novel vaccines and therapeutics for prevention, control, and treatment of the influenza. The global influenza medication market is anticipated to grow at a steady single digit growth rate during the forecast period.
Request PDF Sample: https://www.insightslice.com/request-sample/355
Rising demand and high prescription of Oseltamivir is driving the influenza medication demand
The global influenza medication market is segmented based on product type, sales channel, and geography. Based on product type, the global influenza medication market is segmented into Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and other. The Oseltamivir segment contributed the largest share to the global market in 2019 and is anticipated to witness steady growth during the forecast period owing to the increased adoption post H1N1 pandemic for treatment of flu and prophylaxis. The generic variants of Oseltamivir are anticipated to drive the growth of influenza medication market during the forecast period.
Increasing number of pharmacies and availability of prescription drugs for influenza to fuel sales through pharmacies
Based on sales channel, the global influenza medication market is segmented into hospitals, clinics, pharmacies, and others. The pharmacies contributed the largest share to the global influenza medication market in 2019 owing to increasing number of pharmacies around the globe and is anticipated to witness prominent growth in coming years. The hospital segment is anticipated to offer prominent growth opportunities during the forecast period.
Request For Discount: https://www.insightslice.com/request-discount/355
Based on geography, the global influenza medication market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America contributed the largest share to the global market in 2019 owing to increasing adoption of novel therapeutics for treatment of influenza, growing influx of influenza test across the region, and favourable regulatory & insurance framework. With increasing investment in development of advanced & improved therapeutics, the North America influenza medication market is anticipated to witness prominent growth in coming years. Asia Pacific is expected to witness prominent growth during the forecast period owing to strong prevalence of influenza & increasing number of patients, increasing awareness about influenza, and availability of advanced therapeutics.
Major players active in the global influenza medication market include Alvogen, Amneal Pharmaceuticals LLC, BIOCRYST PHARMACEUTICALS, INC., Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline plc, Lupin Limited, Mylan, Inc., Natco Pharma, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals, Inc.